Chunhua Jiao
University of Iowa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Chunhua Jiao.
Proceedings of the National Academy of Sciences of the United States of America | 2016
Elliott H. Sohn; Hille W. van Dijk; Chunhua Jiao; Pauline H. B. Kok; Woojin Jeong; Nazli Demirkaya; Allison Garmager; Ferdinand W. N. M. Wit; Murat Kucukevcilioglu; Mirjam E. J. van Velthoven; J. Hans DeVries; Robert F. Mullins; Markus H. Kuehn; Reinier O. Schlingemann; Milan Sonka; Frank D. Verbraak; Michael D. Abràmoff
Significance Diabetic retinopathy (DR), a primary cause of blindness, is characterized by microvascular abnormalities. Recent evidence suggests that retinal diabetic neuropathy (RDN) also occurs in people with diabetes, but little is known about the temporal relationship between DR and RDN. This longitudinal study in people with diabetes with no or minimal DR shows that RDN precedes signs of microvasculopathy and that RDN is progressive and independent of glycated hemoglobin, age, and sex. This finding was further confirmed in human donor eyes and in two experimental mouse models of diabetes. The results suggest that RDN is not ischemic in origin and represent a shift in our understanding of the pathophysiology of this complication of diabetes that potentially affects vision in all people with diabetes mellitus. Diabetic retinopathy (DR) has long been recognized as a microvasculopathy, but retinal diabetic neuropathy (RDN), characterized by inner retinal neurodegeneration, also occurs in people with diabetes mellitus (DM). We report that in 45 people with DM and no to minimal DR there was significant, progressive loss of the nerve fiber layer (NFL) (0.25 μm/y) and the ganglion cell (GC)/inner plexiform layer (0.29 μm/y) on optical coherence tomography analysis (OCT) over a 4-y period, independent of glycated hemoglobin, age, and sex. The NFL was significantly thinner (17.3 μm) in the eyes of six donors with DM than in the eyes of six similarly aged control donors (30.4 μm), although retinal capillary density did not differ in the two groups. We confirmed significant, progressive inner retinal thinning in streptozotocin-induced “type 1” and B6.BKS(D)-Leprdb/J “type 2” diabetic mouse models on OCT; immunohistochemistry in type 1 mice showed GC loss but no difference in pericyte density or acellular capillaries. The results suggest that RDN may precede the established clinical and morphometric vascular changes caused by DM and represent a paradigm shift in our understanding of ocular diabetic complications.
Scientific Reports | 2015
Elliott H. Sohn; Chunhua Jiao; Emily E. Kaalberg; Cathryn M. Cranston; Robert F. Mullins; Edwin M. Stone; Budd A. Tucker
Stem cell strategies focused on replacement of RPE cells for the treatment of geographic atrophy are under intense investigation. Although the eye has long been considered immune privileged, there is limited information about the immune response to transplanted cells in the subretinal space of large animals. The purpose of this study was to evaluate the survival of allogenic induced pluripotent stem cell-derived RPE cells (iPSC-RPE) delivered to the subretinal space of the pig as well as determine whether these cells induce an immune response in non-diseased eyes. GFP positive iPSC-RPE, generated from outbred domestic swine, were injected into the subretinal space of vitrectomized miniature swine. Control eyes received vehicle only. GFP positive iPSC-RPE cells were identified in the subretinal space 3 weeks after injection in 5 of 6 eyes. Accompanying GFP-negative cells positive for IgG, CD45 and macrophage markers were also identified in close proximity to the injected iPSC-RPE cells. All subretinal cells were negative for GFAP as well as cell cycle markers. We found that subretinal injection of allogenic iPSC-RPE cells into wild-type mini-pigs can induce the innate immune response. These findings suggest that immunologically matched or autologous donor cells should be considered for clinical RPE cell replacement.
Biomacromolecules | 2018
Brian J. Green; Kristan S. Worthington; Jessica R. Thompson; Spencer J. Bunn; Mary Rethwisch; Emily E. Kaalberg; Chunhua Jiao; Luke A. Wiley; Robert F. Mullins; Edwin M. Stone; Elliott H. Sohn; Budd A. Tucker; C. Allan Guymon
Degradable polymers are integral components in many biomedical polymer applications. The ability of these materials to decompose in situ has become a critical component for tissue engineering, allowing scaffolds to guide cell and tissue growth while facilitating gradual regeneration of native tissue. The objective of this work is to understand the role of prepolymer molecular weight and functionality of photocurable poly(caprolactone) (PCL) in determining reaction kinetics, mechanical properties, polymer degradation, biocompatibility, and suitability for stereolithography. PCL, a degradable polymer used in a number of biomedical applications, was functionalized with acrylate groups to enable photopolymerization and three-dimensional printing via stereolithography. PCL prepolymers with different molecular weights and functionalities were studied to understand the role of molecular structure in reaction kinetics, mechanical properties, and degradation rates. The mechanical properties of photocured PCL were dependent on cross-link density and directly related to the molecular weight and functionality of the prepolymers. High-molecular weight, low-functionality PCLDA prepolymers exhibited a lower modulus and a higher strain at break, while low-molecular weight, high-functionality PCLTA prepolymers exhibited a lower strain at break and a higher modulus. Additionally, degradation profiles of cross-linked PCL followed a similar trend, with low cross-link density leading to degradation times up to 2.5 times shorter than those of more highly cross-linked polymers. Furthermore, photopolymerized PCL showed biocompatibility both in vitro and in vivo, causing no observed detrimental effects on seeded murine-induced pluripotent stem cells or when implanted into pig retinas. Finally, the ability to create three-dimensional PCL structures is shown by fabrication of simple structures using digital light projection stereolithography. Low-molecular weight, high-functionality PCLTA prepolymers printed objects with feature sizes near the hardware resolution limit of 50 μm. This work lays the foundation for future work in fabricating microscale PCL structures for a wide range of tissue regeneration applications.
Retina-the Journal of Retinal and Vitreous Diseases | 2017
Chunhua Jiao; Dean Eliott; Christine Spee; Shikun He; Kai Wang; Robert F. Mullins; David R. Hinton; Elliott H. Sohn
Purpose: We sought to characterize the angiofibrotic and apoptotic effects of vascular endothelial growth factor (VEGF)-inhibition on fibrovascular epiretinal membranes in eyes with traction retinal detachment because of proliferative diabetic retinopathy. Methods: Membranes were excised from 20 eyes of 19 patients (10 randomized to intravitreal bevacizumab, 10 controls) at vitrectomy. Membranes were stained with antibodies targeting connective tissue growth factor (CTGF) or VEGF and colabeled with antibodies directed against endothelial cells (CD31), myofibroblasts, or retinal pigment epithelium markers. Quantitative and colocalization analyses of antibody labeling were obtained through immunofluorescence confocal microscopy. Masson trichrome staining, cell counting of hematoxylin and eosin sections, and terminal dUTP nick-end labeling staining were performed. Results: High levels of fibrosis were observed in both groups. Cell apoptosis was higher (P = 0.05) in bevacizumab-treated membranes compared with controls. The bevacizumab group had a nonsignificant reduction in colocalization in CD31–CTGF and cytokeratin–VEGF studies compared with controls. Vascular endothelial growth factor in extracted membranes was positively correlated with vitreous levels of VEGF; CTGF in extracted membranes was negatively correlated with vitreous levels of CTGF. Conclusion: Bevacizumab suppresses vitreous VEGF levels, but does not significantly alter VEGF or CTGF in diabetic membranes that may be explained by high baseline levels of fibrosis. Bevacizumab may cause apoptosis within fibrovascular membranes.
Molecular Therapy | 2017
Erin R. Burnight; Manav Gupta; Luke A. Wiley; Kristin R. Anfinson; Audrey Tran; Robinson Triboulet; Jeremy M. Hoffmann; Darcey L. Klaahsen; Jeaneen L. Andorf; Chunhua Jiao; Elliott H. Sohn; Malavika K. Adur; Jason W. Ross; Robert F. Mullins; George Q. Daley; Thorsten M. Schlaeger; Edwin M. Stone; Budd A. Tucker
The FASEB Journal | 2017
Katherine N. Gibson-Corley; Kristan S. Worthington; Jessica R. Thompson; Emily E. Kaalberg; Chunhua Jiao; Robert F. Mullins; Edwin M. Stone; Elliott H. Sohn; Budd A. Tucker
Investigative Ophthalmology & Visual Science | 2017
Brittni Scruggs; Erin R. Burnight; Chunhua Jiao; Luke A. Wiley; Robert F. Mullins; Edwin M. Stone; Budd A. Tucker; Elliott H. Sohn
Investigative Ophthalmology & Visual Science | 2017
Elliott H. Sohn; Kristan S. Worthington; Chunhua Jiao; Emily E. Kaalberg; Stephen R. Russell; Katherine N. Gibson-Corley; Robert F. Mullins; Edwin M. Stone; Budd A. Tucker
Investigative Ophthalmology & Visual Science | 2016
Elliott H. Sohn; Chunhua Jiao; Brittni Scruggs; Diana Brack; Edwin M. Stone; Robert F. Mullins; Budd A. Tucker
Investigative Ophthalmology & Visual Science | 2016
Brittni Scruggs; Budd A. Tucker; Chunhua Jiao; Janet Riley; Edwin M. Stone; Robert F. Mullins; Elliott H. Sohn